{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 3 of 129', 'Protocol amendment summary of changes table', 'Document history', 'Document', 'Date', 'Type of protocol amendment', 'Amendment 3', '29-Aug-2018', 'Global', '(substantial)', 'Amendment 2', '10-Apr-2018', 'Global', '(substantial)', 'Amendment 1', '15-Dec-2017', 'Global', '(non-substantial)', 'Original protocol', '04-Oct-2017', 'NA', 'Amendment 3 (29-Aug-2018)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a)', 'of Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall rationale for the amendment', 'The main reason for the amendment is to introduce the possibility for eligible subjects in', 'selected countries to participate to a long-term extension trial (conducted under a separate', 'protocol [LP0162-1337, ECZTEND]) without completing the safety follow-up period in the', 'present trial. Indeed, a new anti-drug antibodies (ADA) assay has been developed with', 'improved tralokinumab tolerance. This means that the presence or absence of ADA can be', 'determined in serum samples with tralokinumab present. Previously, this was not possible and', 'therefore ADA sampling at the end of the 14-week off-treatment safety follow-up was', 'originally required for the ADA evaluation. Thus, in selected countries, the new ADA assay', 'will allow eligible subjects who have completed the treatment periods of the present trial to', 'continue into the long-term extension trial without completing the safety follow-up period in', 'the present trial. These subjects will have their safety follow-up period after end of treatment', 'in the long-term extension trial.', 'Additional changes included in the amendment are presented in the table below.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 4 of 129', 'Note: The table below describes the changes in each section. Changes have either been', 'summarised (written with plain text only) or marked as tracked changes (text added to the', 'protocol is written in bold and deleted text has a line through it).', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Clinical trial', 'Professor PPD', 'is replaced by', 'As a new international coordinating', 'protocol', 'Associate Professor Jonathan', 'investigator was appointed for this', 'statements', 'Silverberg.', 'trial.', 'Section 1', 'Protocol synopsis', 'Appendix 6', 'Contact list', 'Section 1', 'Subjects will have a final safety follow-', 'To clarify that eligible subjects who', 'Protocol synopsis', 'up visit 16 weeks after the last dose of', 'have completed the treatment periods', 'IMP (which is also considered end of', 'of the present trial may continue into', 'Section 4', 'trial visit), except subjects who enter', 'the long-term extension trial', 'Schedule of', 'the long-term extension trial', '(conducted under a separate protocol', 'procedures', '(conducted under a separate protocol', '[LP0162-1337, ECZTEND]) without', 'Panel 3', '[LP0162-1337, ECZTEND]). The', 'completing the safety follow-up', '(footnote 1)', 'subjects may enter ECZTEND at any', 'period.', 'time during the off-treatment safety', 'Section 7.1', 'follow-up period. For these subjects,', 'Overall trial', 'the end of trial visit will be the last visit', 'design', 'in the present trial.', 'The subjects entering ECZTEND after', 'Section 7.3', 'completion of the end of treatment visit', 'End of trial', '(Week 32) will also be considered as', 'definition', 'trial completers. For all subjects', 'assigned treatment, an end of treatment', 'Section 9.9', 'form and end of trial form will be', 'Provision for', 'completed in the eCRF.', 'subject care', 'following trial', 'completion', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 5 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Section 6', 'The following endpoints are added in', 'To allow for a further evaluation of', 'Trial objectives', 'Panel 4 under Other endpoints:', 'the efficacy of tralokinumab+topical', 'and endpoints', 'Reduction from baseline to', 'corticosteroids (TCS) on patient', 'Week 16 of POEM score >4', 'reported outcomes compared with', 'points in subjects with baseline', 'placebo+TCS.', 'POEM score >4.', 'HADS anxiety and HADS', 'depression subscale scores <8', 'at', 'Week 16 in subjects with', 'baseline HADS anxiety or HADS', 'depression subscale scores >8.', 'Section 9.8.2.1', 'The IMP must be stored at 2 to 8\u00b0C at', 'To clarify that the storage', 'Storage of IMPs', 'the site. The temperature during storage', 'temperature of IMP will be', 'must be monitored by a calibrated,', 'monitored.', 'stationary, and continuously', 'monitoring recording-system.', 'Minimum requirement is a calibrated', 'min/max thermometer.', 'Section 9.8.2.2', 'The NIMP must be stored at room', 'To ensure that the NIMP will be', 'Storage of NIMP', 'temperature at the site according to the', 'stored at the trial site according to the', 'approved local label for mometasone', 'approved local label and clarify that', '(te (Canada: 15 30\u00b0C; Europe:', 'the storage temperature of NIMP will', '<25\u00b0C; US: at 25\u00b0C [excursions to 15', 'be monitored.', '30\u00b0C permitted]). The temperature', 'during storage must be monitored by a', 'calibrated, stationary, and continuously', 'monitoring recording system.', 'Minimum requirement is a calibrated', 'min/max thermometer.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}